440 reports of this reaction
2.3% of all POLATUZUMAB VEDOTIN reports
#9 most reported adverse reaction
PYREXIA is the #9 most commonly reported adverse reaction for POLATUZUMAB VEDOTIN, manufactured by Genentech, Inc.. There are 440 FDA adverse event reports linking POLATUZUMAB VEDOTIN to PYREXIA. This represents approximately 2.3% of all 19,009 adverse event reports for this drug.
Patients taking POLATUZUMAB VEDOTIN who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a less commonly reported adverse event for POLATUZUMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to pyrexia, the following adverse reactions have been reported for POLATUZUMAB VEDOTIN:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 440 FDA reports for POLATUZUMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 2.3% of all adverse event reports for POLATUZUMAB VEDOTIN, making it a notable side effect.
If you experience pyrexia while taking POLATUZUMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.